RxDoctor Payments Data

Navdeep Bhatti, MD

Cardiovascular Disease · Munster, INNPI 1538587035

Payments from drug & device makers

$4,943in general payments, 2019–2025

Across 131 payments — averaging $37.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$836
  • Novartis$586
  • Johnson & Johnson$516
  • Amgen$448
  • AstraZeneca$335
  • Boehringer Ingelheim$262
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$75015%
  • Food & beverage$4,10783%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,943 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$67,544
Medicare patients
310
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan50$64,342
EliquisApixaban39$54,844
JardianceEmpagliflozin22$22,082
FarxigaDapagliflozin Propanediol19$20,775
Rosuvastatin Calcium159$2,022
Nifedipine ErNifedipine51$1,418
Metoprolol Succinate87$1,285
Atorvastatin Calcium103$1,075
Ezetimibe12$542
Carvedilol62$509
Amlodipine Besylate84$481
ClopidogrelClopidogrel Bisulfate36$360
Spironolactone52$336
Lisinopril36$308
Furosemide55$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$586$64,34250 claims
PfizerEliquis$234$54,84439 claims
Boehringer IngelheimJardiance$262$22,08222 claims
AstraZenecaFarxiga$335$20,77519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →